This 6-K is routine procedural notice confirming the offering is proceeding. The material event is the 424B5 from May 20, which priced a massive dilutive offering. Monitor for the final prospectus (424B4) to confirm actual offering size, pricing, and net proceeds. Expect continued pressure from dilution overhang until the offering closes and a clearer path to value inflection from the JNJ-1900/NBTXR3 pipeline emerges.
Price Chart
Executive Summary
Nanobiotix announced the resumption of trading of its ordinary shares on Euronext Paris on May 21, 2026, after a same-day halt requested by the company to finalize allocations and announce pricing of a global offering of ADSs, ordinary shares, and pre-funded warrants. The filing is purely procedural—it confirms the offering process advancing, not the results or pricing—and is overshadowed by the prior day's 424B5 filing detailing up to 75M shares of dilution (~155% of shares outstanding). No financial figures, pricing details, or pipeline updates are included.
Key Facts
- Trading on Euronext Paris was halted at the company's request on May 21, 2026 from 9:00 a.m. CEST.
- Trading resumed at 3:30 p.m. Paris time / 9:30 a.m. New York time on the same day.
- The halt was to confirm investor allocations and announce pricing of the previously announced Global Offering.
- The Global Offering includes ADSs in the U.S. and ordinary shares plus pre-funded warrants in Europe/international (ex-U.S./Canada).
- The cross-filing 424B5 (filed May 20, 2026) disclosed a massive dilutive offering of up to 75M shares (~155% of current shares outstanding).
- No offering size, pricing, or proceeds figures are provided in this 6-K filing.
Financial Impact
Dilution of up to ~155% of current shares outstanding per the prior 424B5 filing; proceeds intended to fund pipeline acceleration but magnitude exceeds market cap.
Risk Factors
- Massive dilution of ~155% of shares outstanding from the Global Offering will heavily pressure the stock.
- No pricing details provided; if priced at a steep discount to market, the dilution impact is worse.
- The offering size far exceeds the company's existing market cap, signaling urgent capital needs and high cash burn.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003603 |
| Document: f6k_052126.htm | 0001171843-26-003603 |
| Document: 0001171843-26-003603-index-headers.html | 0001171843-26-003603 |
| Document: 0001171843-26-003603-index.html | 0001171843-26-003603 |
| Document: 0001171843-26-003603.txt | 0001171843-26-003603 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 5, 2026 20w ago | 6-K | — | awaiting T+20 | — | — |
Jun 2, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 424B5 | — | awaiting T+20 | — | — |
May 21, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 21, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 20, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 20, 2026 22w ago | 424B5 | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers